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Abstract
The recent precipitous rise in autoimmune diseases is placing an
increasing clinical and economic burden on health systems
worldwide. Current therapies are only moderately efficacious, often
coupled with adverse side effects. Here, we show that recombinant
human insulin-like growth factor-1 (rhIGF-1) stimulates
proliferation of both human and mouse regulatory T (Treg) cells in
vitro and when delivered systemically via continuous minipump, it
halts autoimmune disease progression in mouse models of type 1
diabetes (STZ and NOD) and multiple sclerosis (EAE) in vivo. rhIGF-1
administration increased Treg cells in affected tissues, maintaining
their suppressive properties. Genetically, ablation of the IGF-1
receptor specifically on Treg cell populations abrogated the benefi-
cial effects of rhIGF-1 administration on the progression of multiple
sclerotic symptoms in the EAE model, establishing a direct effect of
IGF-1 on Treg cell proliferation. These results establish systemically
delivered rhIGF-1 as a specific, effective stimulator of Treg cell
action, underscoring the clinical feasibility of manipulating natural
tolerance mechanisms to suppress autoimmune disease.
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Introduction
The immune system protects adult mammals against pathogens
while restricting those responses to avoid harm to the host.
Active suppression of inflammation and immune responses by
regulatory T (Treg) cells is essential in maintaining this equilib-
rium and immunological self-tolerance (O’Garra & Vieira, 2004;
Littman & Rudensky, 2010). Treg cell-based therapies have held
great promise for restoring tolerance in autoimmune diseases
(Maloy & Powrie, 2001; Wing & Sakaguchi, 2010). Yet efforts to
obtain sufficient cell numbers for transplant, or to develop effec-
tive strategies for boosting endogenous Treg cell function, have
met with limited success.
We have previously implicated IGF-1 as a powerful enhancer
of regenerative responses in multiple tissue types (Musaro et al,
2004; Santini et al 2007, Semenova et al 2010). However, cumula-
tive evidence points to an additional role of the IGF-1/IGF-1R
signaling pathway in regulating the immune response (van Buul-
Offers & Kooijman, 1998; Smith, 2010). In previous work using
autoimmune models, IGF-1 was primarily considered as a pleio-
tropic factor with mitogenic properties that acted mainly on the
affected tissues, enabling their repair while protecting them from
the stress of an immune attack (Smith et al, 1991; Yao et al,
1995; Liu et al, 1997; Agudo et al, 2008). However, to date, IGF-
1-based therapies for selected autoimmune diseases have not been
effective (Lovett-Racke et al, 1998; Cannella et al, 2000; Genoud
et al, 2005).
Here, we define the Treg cell as a direct target of IGF-1 action in
both mouse and human and demonstrate the more general ability of
IGF-1 to control pathological responses in mouse models of autoim-
mune disease, using a clinically relevant continuous delivery proto-
col based on intensive systemic recombinant human IGF-1 release.
These findings establish the efficacy of systemically delivered rhIGF-1,
an FDA-approved therapeutic, in neutralizing autoimmune attack
through local Treg cell recruitment, underscoring the broad applica-
bility of intensive rhIGF-1 therapy in the treatment of autoimmune
disorders.
Results
rhIGF-1 stimulates proliferation of human and mouse Treg cells
ex vivo
To assess the potential effects of rhIGF-1 on Treg cell populations,
Treg (CD4+ CD25+ CD127low) cells were FACS-sorted from human
peripheral blood and analyzed for the transcription factor forkhead
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box P3 (Foxp3), a marker for Treg cells, which was expressed by
> 98% of the sorted population (Fig 1A, Supplementary Fig S1A).
When treated with commercially available rhIGF-1, human Treg
cells showed increased proliferation and FOXP3 expression
compared to untreated cells (Fig 1B and C), underscoring the thera-
peutic relevance of this simple protocol to promote Treg cell prolif-
eration ex vivo.
As in the human cell experiment, a stimulatory role for rhIGF-1
in mouse Treg cell function was documented in vitro by robust
proliferation and FoxP3 activation in FACS-purified Treg cells
treated with rhIGF-1 (Fig 2A and Supplementary Fig S1B). Whereas
in humans, Foxp3 is not directly correlated with T-cell-mediated
suppression (Wang et al, 2007), in the mouse, it is both necessary
and sufficient for Treg development and function (Sakaguchi et al,
2007). Importantly, mouse Treg cells stimulated with rhIGF-1
retained their ability to suppress T effector cell proliferation
(Fig 2B and Supplementary Fig S1C), while the anti-apoptotic effect
of rhIGF-1 (Liu et al, 1997) was not observed (Supplementary
Fig S1D).
rhIGF-1 specifically stimulates proliferation of Treg but not other
T-cell subtypes
A direct link between IGF-1 signaling and Treg activation in vitro
was supported by the abrogation of rhIGF-1-mediated Treg prolifera-
tion through IGF-1R inhibition (Fig 2C) and by the Foxp3 mRNA
induction after rhIGF-1 stimulation (Fig 2D). rhIGF-1 treatment
affected characteristic surface markers of Treg cell activation linked
with proliferation (Fisson et al, 2003), modestly but significantly
upregulating CD71 (Supplementary Figs S1E and S2A) and the acti-
vation marker CD44, and repressing the homing receptor CD62L
(Fig 2E and Supplementary Fig S2A).
Treg proliferation (Fig 2F and Supplementary Fig S2B) and cell
surface marker changes (Supplementary Fig S2A) were dependent
on the activation of a canonical signalling pathway involving the
PI3-kinase–Akt axis (Smith, 2010). Notably, rhIGF-1 had no stimu-
latory effect on CD4+CD25 cells (Th0), or on the in vitro polar-
ized IL-17 (Th17) and IFN-c-secreting (Th1) pro-inflammatory
subsets (Fig 2G), underscoring its potential to alter the balance of
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Figure 1. rhIGF stimulates the proliferation of human Treg cells in vitro.
A FOXP3 expression levels of the sorted human Treg population used in the in vitro assay (red) compared to isotype-labeled cells (blue) showing the purity (> 98%) of
the Treg cells used in the in vitro proliferation assay.
B Representative flow cytometric analysis of treated (rhIGF-1) and control (untreated) human Treg cells stained with Foxp3 and Ki67 antibodies after 6 days of in vitro
culture. Control and treated cells were stimulated with anti-CD3 and CD28 antibodies.
C Flow cytometric analysis of the stimulated and control human Treg cells showing increased Treg cell number after 6 days of culture with rhIGF-1.
[*P(FOXP3+Ki67) = 0.0273; P(FOXP3+Ki67+) = 0.0492; P(FOXP3+) = 0.0393; n = 2].
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Figure 2. rhIGF-1 stimulates murine Treg cell proliferation in vitro.
A FoxP3 and Ki67 flow cytometric analysis of purified mouse CD25+ splenic cells shows increased Treg cells after 2 days stimulation with rhIGF-1. In all in vitro
experiments, cells were stimulated with anti-CD3 and CD28 antibodies.
B Naive murine Treg cells retain their ability to suppress T effector (Teff) cell proliferation in vitro after rhIGF-1 treatment (ratios Treg:Teff, from left to right 1:2, 1:4, 1:8,
1:16, 1:32, 1:64; P = 0.869; n = 3). (See also Supplementary Fig S1C).
C IGF receptor inhibitor (2 lM) blocks IGF-1-mediated expansion of murine Treg cells in vitro (*P = 0.0011; n = 3).
D Foxp3 qRT-PCR analysis of sorted murine CD4+CD25+ cells after the indicated times of rhIGF-1 stimulation shows increase in Foxp3 transcripts compared to
untreated controls (*Pday1 = 0.0379; *Pday2 = 0.0132; n = 2).
E Representative flow cytometric analyses of surface expression markers (CD44 and CD62L) induced by rhIGF-1 on the Treg containing (CD4+CD25+) subset reflecting
murine Treg cell activation.
F Flow cytometric analysis showing the effect of inhibitors of AKT (Deguelin, 1 lM; Deg), PI3-kinase (Ly-294,002, 10 lM; LY) and MAPK (PD.98,059, 10 lM; PD) on the
proliferation of murine Treg cells after 2-day treatment with rhIGF-1 (*P = 0.0059; n = 2).
G rhIGF-1 expands the Treg cell subset (FoxP3+) but not CD4+CD25 (Th0) or pro-inflammatory murine subsets Th1 (IFN-c+) and Th17 (IL-17+), which remained
unchanged after 2 days polarization and 3-day incubation with rhIGF-1 (*P = 0.0268; n = 3).
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regulatory/pro-inflammatory cell subsets leading to a more immu-
nosuppressive environment. Taken together, these data support a
specific role for IGF-1 in positively regulating Treg cell-mediated
immunosuppression.
rhIGF-1 induces novel gene expression patterns associated with
proliferation in Treg cells
To further characterize the effects of IGF-1 on the Treg cell
subset, we compared gene expression profiling of FACS-sorted
mouse FoxP3+ cells to those stimulated with rhIGF-1 (Supplemen-
tary Table S1), which upregulated the majority of the overlapping
23 Treg cell signature genes (Hill et al, 2007) (Fig 3A). Of the
seven canonical clusters of highly co-regulated genes within the
Treg cell signature (Hill et al, 2007), two clusters (4 and 6,
Fig 3B) were significantly affected by rhIGF-1 treatment. Cluster 4
includes genes directly responsive to TCR and IL-2 cues, consis-
tent with the induction of Treg cell proliferation. Cluster 6,
however, includes orphan genes not influenced by cell activation,
TGF-b or FoxP3 (Supplementary Table S2). Transcription target
enrichment analysis of Cluster 6 identified different gene sets
associated with E2F transcription factors (Supplementary Table
S3) involved in the regulation of cell cycle and proliferation
(Johnson et al, 1993). Taken together, these results confirm that
IGF-1 modulates a novel expression pattern of genes involved in
Treg cell proliferation.
Systemic delivery of IGF-1 protects from drug-induced and
genetic diabetes
Type-1 diabetes (T1D) is an autoimmune disease caused by T-cell-
induced destruction of the insulin-producing b-cells of the pancreas
(Atkinson & Leiter, 1999). Disruption of the homeostatic balance of
autoaggressive cells and Treg cells promotes T1D (Waid et al,
2008). To test the therapeutic potential of systemic rhIGF-1 delivery
in T1D, wild-type C57/Bl6J female mice were implanted with a
subcutaneous osmotic minipump containing rhIGF-1 and diabetes
was induced by multiple low-dose streptozotocin (STZ) injections
(Like & Rosini, 1976; Rossini et al, 1978; Paik et al, 1980; Nakamura
et al, 1984; Linn et al, 1987; Cockfield et al, 1989; Yanagawa et al,
1989; Papaccio et al, 1994; Lukic et al, 1998; Stosic-Grujicic et al,
2009; Wen et al, 2009; Zdravkovic et al, 2009). Minipumps
provided steady elevated systemic rhIGF-1 levels over 3 weeks
(Supplementary Fig S2C). No adverse reaction to the human IGF-1
protein was seen, presumably due to the high sequence conserva-
tion with the mouse.
STZ treatment induced the first signs of deregulated glucose
homeostasis after 3 weeks (Fig 4A and Supplementary Fig S2D).
Similar to the effects previously observed in diabetic patients
(LeRoith & Yakar, 2007), systemic delivery of rhIGF-1 improved
glycemic control in these animals (Fig 4A and Supplementary Fig
S2D). Notably, rhIGF-1 administration resulted in improved glucose
homeostasis well beyond its direct hypoglycemic effects (LeRoith &
Yakar, 2007) (Fig 4A), providing long-lasting protection of the cell
mass and architecture of the glucose-responsive insulin-producing
pancreatic islands (Fig 4B and Supplementary Fig S2E). Treatment
with rhIGF-1 had no effect on glucose control in non-diabetic
controls (Supplementary Fig S2F).
Since the homeostatic balance of Treg cells and auto-aggressive
cells is critical in the development of autoimmune diabetes (Waid
et al, 2008; Feuerer et al, 2009; Bluestone et al, 2010), we examined
Treg cell numbers in peripheral blood and spleen. Measuring FoxP3
expression, we confirmed an increase in the absolute Treg cell
numbers and those relative to CD4 after subcutaneous implantation
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Figure 3. rhIGF-1 modulates the Treg cell transcriptional landscape.
A Microarray analysis of 23 genes differentially expressed (> 2X) in Treg cells
upon rhIGF-I stimulation (IGF) that overlap with the Treg signature (Treg)
as defined by Hill et al (2007). Lower panel corresponds to a heatmap
showing how this gene set is largely upregulated upon IGF-I stimulation
(P = 0.025).
B rhIGF-1 treatment affects the expression of Treg signature genes (upper
left subpanel; P = 0.004) and different functional clusters (as defined by
Hill et al, 2007). Of the different clusters defined by Hill et al, only genes
belonging to Cluster 4 (directly responsive to TCR and IL-2 cues;
P = 0.0004) and Cluster 6 (not influenced by activation, TGF-b signaling
or FoxP3; P = 0.001) are significantly upregulated by rhIGF-I treatment.
Each gray horizontal line represents a gene expression level along an
arbitrary unit (AU) scale on the y-axis. Average expression for each lane
within each cluster is shown as a horizontal black line. The asterisk in
subpanels “Treg” and Clusters 4 and 6 indicates significant
differential expression between CTR (control) and IGF (rhIGF-I) treatment.
*P < 0.05.
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of rhIGF-1 minipumps (Fig 4C and Supplementary Fig S2G–J), while
CD4+ cells remain unchanged or decreased in peripheral blood or
spleen, respectively (Supplementary Fig S2K and L). Increased Treg
cells were also observed in the pancreata of STZ diabetic mice
treated with rhIGF-1, as revealed by immunostaining against FoxP3
in diabetic or untreated mice (Fig 4D and E). Thus, relatively short
but constant rhIGF-I treatment prevents the development and
progression of disease by increasing peripheral Treg cell numbers
and stably recruiting them to damaged pancreatic tissue, preventing
islet degeneration.
As the STZ model of T1D is caused by direct toxicity to pancre-
atic b-cells (Lenzen, 2008), we also tested an alternative, genetic
model of T1D, the non-obese diabetic (NOD) mouse, which sponta-
neously develops autoimmune diabetes at 10 weeks (Anderson &
Bluestone, 2005). NOD mice were implanted with a subcutaneous
osmotic minipump containing rhIGF-1 before diabetes onset (from
CTRL IGF-1 CTRL IGF-1
0.0
0.2
0.4
0.6
0.8
Fo
xP
3-
po
si
t iv
e
c e
lls
in
b l
oo
d
(%
)
Treg Treg (Ki67+)
*
*
0 20 40 60 80 100 120
0
10000
20000
30000
40000
50000
IGF-1
CTRL
UNT
Time (days)
A
U
C
PUMPA
CTRL IGF-1 UNT
0
2
4
6
Fo
xP
3-
po
si
tiv
e
ce
l ls
pe
ru
n i
t a
re
a
STZ
*
E
D
B
CTRL IGF-1 UNT
STZ
INSULIN
C
10 33 39
0
20000
40000
60000
80000
100000
CTRL
IGF-1
Time (weeks)
AU
C
*
F
25 30 35 40 45
0
20
40
60
80
100
CTRL
IGF-1
Time (weeks)
P
er
ce
nt
 s
ur
vi
v a
l
G
FoxP3
CTRL IGF-1 UNT
STZ
Figure 4. Systemic delivery of IGF-I protects from low-dose STZ-induced and spontaneous diabetes and increases pancreatic Treg cell numbers.
A Glucose tolerance tests (GTT) were performed at the indicated times from the first STZ injection, and the area under the curve (AUC) was calculated. rhIGF-1
delivery during 28 days (gray box; PUMP) improved glucose homeostasis (P22d = 0.143, P37d = 0.016, P89d = 0.036; n = 13).
B Insulin staining of day 97 pancreas reveals long-lasting protective effects of rhIGF-1 treatment on pancreatic cell mass and architecture in rhIGF-1-treated mice
(IGF-1) compared to STZ-treated (CTRL) and untreated (UNT) mice. Bar = 0.1 mm.
C Flow cytometric analysis of peripheral blood 1 week after implantation of rhIGF-1 minipumps shows increased FoxP3+ (Treg; P = 0.011, n = 13) and KI67+ (Treg
Ki67; P = 0.007) Treg cells in STZ-treated animals. *P < 0.05.
D, E Immunohistochemical analysis showing increased infiltration of FoxP3+ cells in pancreatic tissue of rhIGF-1-treated mice (*P = 0.015; n = 12) compared to STZ-
treated (CTRL) and untreated (UNT) mice. Bar corresponds to 0.1 mm.
F Glucose tolerance tests (GTT) were performed at the indicated times, and the area under the curve was calculated (AUC). Systemic rhIGF-1 delivery during 28 days
(week 9–12) ameliorates diabetes progression in NOD mice (IGF-1; P33w = 0.007, P39w = 0.053; n = 14) compared to control mice (CTRL). *P < 0.05.
G Systemic rhIGF-1 delivery increases NOD survival rate (P = 0.015; n = 14).
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 11 | 2014
Daniel Bilbao et al IGF-1 suppresses autoimmune disease EMBO Molecular Medicine
1427
week 9 to 12). As previously shown by daily subcutaneous injections
of rhIGF-1 to prediabetic NOD mice (Bergerot et al, 1995; Kaino
et al, 1996), we observed a delayed onset of diabetes symptoms.
rhIGF-1 treatment not only improved glucose homeostasis (Fig 4F
and Supplementary Fig S2M) but also reduced mortality (Fig 4G).
Thus, continuous systemic delivery of rhIGF-1 afforded protection
from both environmentally induced and spontaneous T1D.
EAE amelioration after rhIGF-1 treatment is dependent on Treg
cell function
To establish a broader role for IGF-1 in restoring immune tolerance,
we exploited a murine model of multiple sclerosis, a chronic auto-
immune demyelinating disease of unknown etiology. After subcuta-
neous implantation of rhIGF-1 minipumps, experimental
autoimmune encephalomyelitis (EAE) was induced in mice with
peptide MOG35-55 immunogen as described (see Materials and Meth-
ods). rhIGF-1 improved the clinical outcome of the disease, with
consistently beneficial effects after the third week post-disease
induction (Fig 5A). Treg cell numbers were increased in the spinal
cords of rhIGF-1-treated animals at the early stages of the disease
(Fig 5B and C). Both clinical improvement and increased Treg cell
numbers associated with rhIGF-1 treatment soon after disease onset
were abolished by CTLA-4 blockade (Supplementary Fig S3A–C),
which interferes with Treg cell function (Herman et al, 2004),
suggesting that the effects of rhIGF-1 on the T regulatory subset are
required for the amelioration of the disease.
The beneficial action of rhIGF-1 extended to a more therapeuti-
cally relevant intervention when delivered after appearance of the
first signs of EAE-induced paralysis. Reduction in clinical severity
was observed soon after the initiation of rhIGF-1 treatment at day
11 post-MOG35–55 immunization (Fig 5E), which was as effective in
reducing mortality as when administered prophylactically (Fig 5F).
As in the diabetic model, rhIGF-1 increased the number of Treg cells
in the affected tissue and improved clinical outcome.
IGF-1/IGF-1 receptor axis directly regulates Treg cell proliferation
and function in vivo
The effects of rhIGF-1 described above could be explained by its
direct stimulatory action on proliferation of the Treg subset, on
increased Treg cell activation and migration to the damaged tissue,
or a combination of both. A direct role for IGF-1 on Treg cell prolif-
eration was assigned by analyzing mice carrying a Treg cell-specific
deletion of the IGF-1 receptor (designated CKO). CKO mice were
generated by crossing mice carrying a Foxp3 EGFP/Cre fusion
cassette (Zhou et al, 2009) with an Exon3-floxed allele of the IGF-1R
gene (Foxp3creIgf1rfl/fl (Temmerman et al, 2010) (Supplementary Fig
S3D). CKO mice were indistinguishable from Foxp3cre and Igf1rfl/fl
controls (CTRL) (Supplementary Fig S3E–I) until subjected to
immune challenge (contact hypersensitivity, CHS), whereupon Treg
cells showed reduced FoxP3 expression levels (Fig 6A and B), as
well as a decrease in cell number and proliferative status (Fig 6C, D
and Supplementary Figs S3J, K, and S4A–C). No phenotypic differ-
ences were noted between CTRL genotypes (Supplementary Tables
S4 and S5).
Western blot analysis of IGF-1 receptor levels in CD4+ cell popu-
lations (Treg and T conventional (Tconv) cells, CD4+CD25CD44+
and CD4+CD25CD62L+) from CTRL and CKO mice showed deple-
tion of the IGF-1 receptor specifically in the CD4+CD25+ Treg
containing population (Fig 6E). T-cell activation also induced IGF-1
receptor expression in CTRL Tconv cells, albeit at lower levels in
the CKO background. This was presumably due to indirect feedback
from Treg CKO cells, as no Foxp3Cre (GFP) expression was evident
in these cells (Supplementary Fig S4D and E).
When tested in the EAE model, the collective therapeutic effect
of rhIGF-1 was completely abolished in the CKO background
(Fig 6F) establishing a direct link between blockade of disease
progression and IGF-1-mediated Treg cell activation. Together, these
data demonstrate that IGF-1 directly and specifically stimulates the
proliferation of Treg cells in vivo, and provide a mechanism
whereby IGF-I can modulate the quality and the amplitude of the
immune response to inflammatory insults.
Discussion
In this study, we report on the direct activation of human and
mouse Treg cell proliferation by rhIGF-1 and demonstrate how a
confined period of continuous systemic rhIGF-1 delivery using a
clinically relevant, accepted method for delivering drugs in humans
(Yaturu, 2013) is a feasible and readily applicable therapeutic
avenue for the treatment of autoimmune and inflammatory
diseases. Although recombinant IGF-1 is already in widespread use
for the treatment of short stature in children (Richmond & Rogol,
2008), results in treating chronic disease have been mixed. Early
studies of systemic IGF-1 delivery in diabetic patients led to
decreased glucose and insulin levels during the time of administra-
tion, improving glycemic control (Zenobi et al, 1992; Carroll et al,
1998; LeRoith & Yakar, 2007). In a large study, diabetic subjects
receiving IGF-I for 12 weeks experienced major decreases in insulin
requirements (Morrow et al, 1994), but side effects included edema,
jaw pain, tachycardia and worsening of retinopathy (Quattrin et al,
1997).
The effects of IGF-1 have also been tested in different models for
multiple sclerosis. Initial reports (Yao et al, 1995; Liu et al, 1997
and references therein) assumed a direct effect of IGF-1 on oligoden-
drocytes and myelin regeneration, resulting in clinical amelioration.
However, in subsequent studies, Lovett-Racke et al (1998) failed to
observe any protection when IGF-1 was administered after disease
onset or during the chronic phase of the disease (Cannella et al,
2000). Local IGF-1 administration also showed no effect on remyeli-
nation of aged mice (O’Leary et al, 2002) or on protection of mice
from EAE (Genoud et al, 2005). Collectively, these studies indicated
that IGF-1 therapy provided little protection and could even be dele-
terious if delivered together with IGFBP3 after disease onset (Lovett-
Racke et al, 1998).
In contrast to these reports, we observed significant and lasting
improvements in animal models of immune disease treated with a
relatively short but uninterrupted supply of systemic rhIGF-1. The
beneficial effects of rhIGF-1 on glucose homeostasis in diabetic mice
extended far beyond the treatment itself, indicating durable
improvement in pancreatic function. In the EAE model, continuous
rhIGF-1 delivery produced clear amelioration even after the antigen
response was triggered, presumably due to blockade of autoimmune
progression and re-establishment of tolerance.
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Despite extensive study, the precise mechanism of IGF-1 action
in countering autoimmune disease has remained obscure. Previ-
ous reports implicating IGF-1 in the prevention of T1D develop-
ment (Bergerot et al, 1995; Kaino et al, 1996; George et al, 2002;
Chen et al, 2004; Casellas et al, 2006; Agudo et al, 2008) have
cited its mitogenic properties (Smith et al, 1991; Le Roith, 1997)
mainly acting on the affected tissues, while protecting them from
the stress caused by the autoimmune attack. By establishing Treg
cells as a critical contributor to the therapeutic effects of systemic
IGF-1 delivery in autoimmune disease, our report builds on previ-
ous studies documenting decreased Treg numbers and FoxP3
expression in the inflamed pancreas of autoimmune mice (Feuerer
et al, 2009; Bluestone et al, 2010). Although a recent study found
intrapancreatic Treg cell numbers were increased by IGF-1 over-
expression in the liver of STZ-treated mice (Anguela et al, 2013),
an indirect effect was proposed, mediated by IL-7-producing
dendritic cells that improved Treg survival or by the conversion
of conventional T cells into Treg cells by TGF-b secreted from the
liver. In contrast, the current study shows that the protective
action of exogenous rhIGF-1 against autoimmune insults can be
attributed to the direct stimulation of Treg cell proliferation, a
key finding given that continuous self-renewal is the major mech-
anism of maintenance of this lineage in adulthood (Rubtsov et al,
2010).
Using a continuous delivery protocol, we show that rhIGF-1
not only stimulates proliferation of Treg cells but also alters their
trafficking, allowing for homing in the damaged organ. Although
significant numbers of Treg cells localize to the spinal cord during
EAE (Korn et al, 2007; this work), their activity appears insuffi-
cient to prevent the autoimmune response. Webster et al (2009)
showed that a well-defined Treg cell-stimulating cytokine (IL-2)
led to a widespread expansion of this subset and to disease
protection. However, this effect was only observed when IL-2
treatment preceded disease onset. However, unlike IGF-1, IL-2
treatment failed to induce Treg recruitment to the injured tissue.
The inability of the expanded Treg cells to home in the damaged
tissue might also lie behind the failure of an IL-2-based therapy
for diabetes (Long et al, 2013); indeed, supplementation with IL-2
further augmented the proliferative effects of rhIGF-1 on Tregs in
vitro. Consistent with the report of a CD44hi Treg subset with
high proliferative activity in vivo (Min et al, 2007), we show here
that Treg cells treated with rhIGF-1 acquire an activated memory-
like phenotype (CD44hi, CD62Llo; Feuerer et al, 2009; Campbell &
Koch, 2011), allowing them to effectively migrate to areas of
inflammatory activity rather than to secondary lymphoid organs
(Fisson et al, 2003; Bromley et al, 2008). Thus, continuous rhIGF-1
delivery is an attractive option for the therapeutic treatment of
even advanced autoimmune patients.
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Figure 5. EAE amelioration after rhIGF-1 treatment is dependent on Treg cell function.
A Clinical grading (1: no clinical signs; 4: forelimbs paralyzed) determined over 4 weeks after rhIGF-1 treatment, initiated 3 days before immunization with MOG35–55
peptide (day 0) (P = 0.01; n = 13).
B Mice treated with MOG35–55 peptide
+/ rhIGF-1 as in (A) showed increased FoxP3 infiltrating cells in the spinal cord induced by rhIGF-1 treatment (P = 0.014; n = 15).
C rhIGF-1 minipumps implanted after EAE induction when the first signs of disease appeared (day 11, see arrow) reduced clinical severity by 58% percent (e.g. day 26;
P = 0.0296; n = 18).
D rhIGF-1 increased survival rates (n = 34, P = 0.028, log-rank test for trend) when administered before or after the induction of EAE.
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Although a number of autoimmune diseases have been superfi-
cially examined for their potential association with abnormalities in
the IGF-I/IGF-IR pathway (Smith, 2010), a substantial link between
this pathway and the pathogenesis of these diseases has not been
established. What is the precise role played by IGF-1/IGF-1R signal-
ing in Treg cells? Continuous expression of FoxP3 is needed to main-
tain lineage identity and function of mature Treg cells (Williams &
Rudensky, 2007), such that attenuation or loss of FoxP3 expression
leads to defective Treg suppressive function and conversion into
effector cells, enhancing rather than inhibiting the immune disease
state (Wan & Flavell, 2007; Zhou et al, 2009). We therefore surmise
that the therapeutic effects of rhIGF-1 delivery occur through direct
stimulation of IGF-1R signaling, which stabilizes the Treg transcrip-
tional landscape and enhances FoxP3 expression.
Of note in this respect is the ability of IGF-1 to specifically affect
two Treg signature clusters of co-regulated genes (Clusters 4 and 6)
not directly controlled by FoxP3 (Hill et al, 2007). Whereas genes in
Cluster 4 are related to proliferation and activation, Cluster 6
contains genes for which IGF-1 seems to be a new regulator. Among
the genes belonging to this latter cluster is the IGF-1 receptor itself
(Hill et al, 2007), which stimulates proliferation and maintenance of
Treg cells in vivo (Rubtsov et al, 2010).
By establishing a direct link between IGF-1 signaling, Treg cell
activation and the re-establishment of the immune balance, we
provide a rational for reinterpreting the findings and failures of past
approaches (e.g. expressing IGF-1 in cells of the CNS in EAE
models), protocols (e.g. short-term delivery of IGF-1 with only tran-
sient beneficial effects) and delivery methods (continuous delivery
by pumping device versus subcutaneous injections). Together with
a parallel study, in which allergic contact dermatitis was suppr-
essed through IGF-1-mediated Treg cell activation (Johannesson
et al, 2014), our results provide a viable protocol for stimulat-
ing human Treg cell proliferation in vitro and in vivo and will also
help in the search for appropriate clinical and surrogate markers for
Treg cell expansion to aid in successful experimental and clinical
design of autoimmune therapies. Given recent evidence of Treg
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Figure 6. IGF-1/IGF-1 receptor axis regulates the proliferation and function of Treg cells in vivo.
A, B IGF-1 receptor-deficient Treg cells (Foxp3cre Igf1rfl/fl) express lower levels of FoxP3 (mean fluorescent intensity; *P < 0.001, n = 16) upon contact hypersensitivity
challenge.
C Flow cytometric analysis of Foxp3cre Igf1rfl/fl (KO), Igf1rfl/+ and Igf1rfl/fl (CTRL) peripheral blood CD4+ cells showing decreased FoxP3+ Treg cells in contact-
hypersensitized Foxp3cre Igf1rfl/fl mice (n = 26; *P = 0.0049; **P = 0.021).
D Representative flow cytometric analysis of splenic FoxP3+ cells shows decreased proliferation (Ki67 expression) in Treg cells of contact-hypersensitized Foxp3cre
Igf1rfl/fl mice. Tinted plot corresponds to isotype control.
E Top panel: IGF-1 receptor Western blot analysis of different populations of CD4-positive cells from Igf1rfl/fl (CTRL) and Foxp3cre Igf1rfl/fl (KO) mice showing specific
deletion of the IGF-1 receptor in the CKO Treg population. Lanes 1, 2: Treg cells (CD4+CD25high), Lanes 3, 5: memory CD4+CD25CD44+CD62L T cells; Lanes 4, 6:
naive CD4+CD25CD44CD62+ T cells. Bottom panel: Loading controls (b-actin).
F rhIGF-1 minipumps were implanted after EAE induction when the first signs of disease appeared as in Fig 5E (day 11) and clinical grading was determined over a
period of 4 weeks (2-way ANOVA, P = 0.048, n = 36).
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involvement in muscle repair (Burzyn et al, 2013), it is likely that
local stimulation of Treg cell expansion by IGF-1 may contribute
to its well-documented beneficial effects in tissue regeneration as
well.
Materials and Methods
In vivo experiments
All mice used were on a C57BL/6J genetic background unless other-
wise indicated. Igf1rfl/flFoxp3cre mice were generated by crossing
Igf1rfl/fl (C57BL/6J; Jackson Laboratory; Temmerman et al, 2010)
and Foxp3cre (NOD; Jackson Laboratory; Efstratiadis et al, 2008)
mice. rhIGF-1 (Biovision) was delivered continuously (0.25 ll/h,
28-day release) via subcutaneously implanted Alzet osmotic mini-
pump (model #2004, Alzet Osmotic Pumps Company) at a dose of
0.275 mg/kg/day. Surgical implantation of the osmotic minipumps
was performed 1 week before the induction of diabetes or EAE,
unless otherwise indicated. Control mice were either sham-operated
mice or implanted with PBS (solvent)-delivering pumps, as no
difference was observed between these two groups compared to
rhIGF-1-delivering pumps (Supplementary Fig S4F). rhIGF-I levels
were determined by ELISA (Human IGF-I Quantikine, R&D) accord-
ing to the manufacturer’s protocol.
Mice were maintained at EMBL Monterotondo Laboratory
Animal Facility. All mouse procedures were approved by the EMBL
Monterotondo Ethical Committee (Monterotondo, Italy) and were in
accordance with national and European regulations. All animal
colonies are housed in accordance with the European Legal frame-
work that exists for the protection of animals used for experimental
and other scientific purposes (European convention ETS123/Coun-
cil of Europe, European directive 86/609/EEC and the recently
published Directive2010/63/EU) as well as the current Guidelines
of International Organizations such as the Association for the
Assessment and Accreditation of Laboratory Animal Care Interna-
tional (AAALAC) and the Federation of European Laboratory
Animal Science Association (FELASA). The macroclimate of the
facility is controlled via a central monitoring unit; thus, the condi-
tions of temperature, humidity, ventilation, air changes and dark/
light cycles are under strict limits. Animals are hosted under
specific pathogen-free (SPF) conditions in individual ventilated
cages (IVC) and isolators. The animal facilities are subjected to a
complete veterinary medical care program by the responsible veteri-
narian and manager (LAS specialist FELASA cat.D) which includes
preventive medicine, surveillance, diagnosis, treatment and control
of diseases as well as veterinary care of the animals used in experi-
mental protocols. A health-monitoring program is also in force, in
accordance with the guidelines issued by FELASA. The surveillance
system personnel are also responsible for determining the humane
end points and for deciding whether the animals should be eutha-
nized in order to avoid further suffering. The 3Rs principle is routi-
nely implemented in our experimental design in order to minimize
the use of animals. Special attention is taken to minimize the number
of animals included in each study, and experiments are designed to
obtain maximum amount of data from each experimental mouse.
Human data were obtained under informed consent and using
procedures and protocols approved by the EMBL Bioethics Internal
Advisory Committee (BIAC) and conforming to the principles set
out in the WMA Declaration of Helsinki and the NIH Belmont
Report.
Diabetes experiments were performed using NOD mice (Jackson
Laboratory), or C57BL/6J mice as described in the Low-Dose Strep-
tozotocin Induction Protocol (Diabetic Complications Consortium).
(http://www.diacomp.org/shared/showFile.aspx?doctypeid=3&do
cid=19). Briefly, freshly prepared streptozotocin (Sigma) solution
was injected intraperitoneally at a dose of 40 mg/kg. Mice received
one injection each day for 5 days consecutively. Glucose homeosta-
sis was determined at the indicated time points using an intraperito-
neal glucose tolerance test (Heikkinen et al, 2007). After having
measured basal blood glucose concentrations, a 20% aqueous
glucose solution was administered intraperitoneally to fasted mice
at a dose of 2 g glucose/kg. Clearance of glucose in blood was
measured at 30-min intervals for a period of 3 h. For statistical
analysis, the area under the curve was calculated using Prism
(GraphPad Software).
EAE experiments were performed as described (Stromnes &
Goverman, 2006) using the peptide MOG35–55 as an immunogen.
Briefly, mice were injected with a 1:1 emulsion of the MOG35–55
peptide (200 lg/mouse; AnaSpec) and complete Freund’s adjuvant
(Sigma) at day 0. Two doses of pertussis toxin (400 ng/mouse;
Sigma) were administered at day 0 and day 2. Mice were then
monitored for clinical signs and weight loss. Clinical severity was
scored using a grading scale 0–5 where the following grades corre-
spond to the indicated clinical signs (0, No clinical signs; 0.5,
Partially limp tail; 1, Paralyzed tail; 2, Loss in coordinated move-
ment, hind limb paresis; 2.5, One hind limb paralyzed; 3, Both hind
limbs paralyzed; 3.5, Hind limbs paralyzed, weakness in forelimbs;
4, Forelimbs paralyzed; 5, Moribund). In the experiment recreating
therapeutic intervention with Igf1rfl/flFoxp3cre mice, rhIGF-1 mini-
pumps were implanted after EAE induction when the first signs of
disease appeared and clinical grading was determined over a period
of 4 weeks, and only in mice showing symptoms of paralysis for at
least two consecutive days. Where indicated, mice were injected at
day 0 with purified anti-CTLA-4 (UC10.4F10.11, BD Pharmingen)
antibody or isotype control (A95-1; BD Horizon) at a dose of
0.6 mg/mouse.
Direct proliferative stimulation of Treg cells by IGF-I in vivo was
determined by flow cytometric analysis of CD4-positive cells from
Igf1rfl/flFoxp3cre spleens in the context of a contact hypersensitivity
response (Klekotka et al, 2010). Briefly, mice were sensitized on the
abdomen with 50 ll of 0.5% DNFB (Sigma-Aldrich, Saint Louis,
MO) on day 0 and day 1. Flow cytometric analysis of the spleens
was performed on day 3 after elicitation. After tissue disaggregation,
single cell suspensions were blocked with anti-CD16/32 and further
stained with anti-CD4, FoxP3 and Ki67 antibodies according to the
manufacturer’s protocol.
Histological analysis
Tissues were fixed in 4% formaldehyde overnight, dehydrated in an
increasing gradient of ethanol and embedded in paraffin. In EAE
experiments, parts of the vertebral column containing the spinal
cord were fixed, decalcified in 0.5% EDTA for a week prior to
embedding. Ten-micrometer sections were made and then dewaxed
and rehydrated in an ethanol gradient. For FoxP3 and CD4
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stainings, heat antigen retrieval was performed and endogenous
peroxidase was quenched by a 10-min incubation in 1% H2O2. After
blocking with 2% NGS, immunostaining was performed using a
FoxP3 antibody (Abcam) and a secondary anti-rabbit-AP (Sigma),
CD4 (Abcam) or proinsulin (Abcam) and Vectastain ABC kit accord-
ing to the manufacturer’s protocol. DAB solution (Sigma) was used
for signal detection with HRP-conjugated antibodies or NBT/BCIP
(Roche) with AP-conjugated antibodies. Proinsulin-stained sections
were counterstained with hematoxylin.
Images were captured using a LMD7000 (Leica) microscope and
quantified manually using ImageJ cell counter. At least three
sections from each mouse separated from each other by 50 lm were
analyzed.
In vitro experiments
Antibodies against CD16/32 (Clon 93), CD4 (GK1.5), CD25
(PC61.5), FoxP3 (FJK-16F), IFN-c (XMG1.2), IL-17 (eBio17B7),
CD71 (RI7 217.1.4) and CD44 (IM7) were purchased from eBio-
science. Anti-CD62L (MEL-14), anti-Ki-67 and annexin V were
purchased from BD Pharmingen. For the experiment with human
cells, antibodies were purchased from BD Pharmingen, including
the regulatory T-cell cocktail, FoxP3 staining kit and buffer set.
Surface and intracellular stainings were performed according to the
manufacturer’s protocol. For the Western blot analysis, a rabbit
mAb IGF-I Receptor b (D23H3) XP (Cell signaling Technology) was
used.
For in vitro murine proliferation experiments, cells were isolated
from spleens of C57BL/6 mice. After red blood lysis, cells were incu-
bated sequentially with anti-CD16/32 and directly labeled anti-CD4
and CD25 antibodies. CD4 CD25 double-positive cells were then sorted
with a standard three-laser FACS Aria or a 5-laser FACS Aria SORP
from BD (70 lm nozzle, 70 psi; > 98% purity) and stimulated with
coated anti-CD3 (17A2, eBioscience) and soluble anti-CD28 (37.51,
eBioscience) and the indicated factors or inhibitors (IGF-1R inhibitor
PPP, Calbiochem; Ly-294,002, Sigma; Deguelin, Sigma; PD.98,059,
Sigma). IGF-1 was used at a concentration of 25–100 ng/ml unless
otherwise indicated.
For the in vitro human proliferation experiment, mononuclear
cells from EDTA-treated blood were isolated by Ficoll-hypaque
(Pharmacia Biotech) gradient centrifugation and stained with the
human T regulatory cocktail. Treg cells were then sorted using a
5-laser FACS Aria SORP from BD (85-lm nozzle, 40 psi; > 98%
purity) and stimulated with anti-CD3/anti-CD28-coated beads
(Gibco), and the indicated factors in RPMI supplemented with
10% FCS for a period of 6 days. After surface staining, cells were
fixed and stained for FoxP3 and Ki67 and analyzed in a FACS
Aria SORP.
For in vitro polarization experiments, FACS-purified CD4-positive
CD25-negative cells were pre-incubated for 3–5 days with IFN-c
(PeproTech), IL-12 (PeproTech) and anti-IL-4 antibodies (11B11;
eBioscience) (Th1) or TGF-b (PeproTech), IL-6 (PeproTech), anti-
IL-4, anti-IL12 (C17.8; eBioscience) and IFN-c (AN-18; eBioscience)
antibodies (Th17). The number of FoxP3-positive cells was deter-
mined by flow cytometric analysis in a two-laser FACS Canto (BD
Biosciences) or a FACS Aria (BD Biosciences) after intracellular
staining according to the manufacturer’s protocol (IC fixation buffer
or FoxP3 staining buffer set, eBioscience). Data analysis was
The paper explained
Problem
Autoimmune diseases are increasingly widespread, threatening to
surpass other well-recognized medical conditions such as heart
disease or cancer. Due to their prevalence, these diseases not only
affect the lives of those who suffer their devastating consequences,
but strain the economies of healthcare systems. Current treatment
modalities show moderate effects and rely on suppressing the imbal-
anced immune system to avoid the persistent inflammation and
tissue damage caused by autoimmunity. However, these treatments
inevitably lead to serious adverse long-term effects. In healthy
subjects, the immune system is in a state of equilibrium that allows
for a rapid and accurate protective response against pathogens while
restricting responses causing harm to the host. In autoimmune
patients, this equilibrium is lost and the immune system fails to
distinguish self from non-self. T regulatory cells (Treg cells) are subject
of intensive clinical research as they are key players in this process,
acting as committed suppressors of inflammation, controlling normal
immune responses and self-tolerance. When injected, they improve
immunosuppression in organ transplants and also halt autoimmune
progression. However, because of the technical challenges of produc-
ing enough functional numbers of these cells and the high associated
costs, researchers are seeking alternative approaches, such as safe
drugs that will expand these regulatory cell numbers within the body.
Results
In this study, we prove the feasibility of a novel IGF-1 delivery method
in combating autoimmune disease and identify IGF-1 as a naturally
occurring growth factor that leads to Treg cell expansion, activation
and migration into affected tissues, producing long-term immune
tolerance and improved clinical outcome. Using the intensive but clin-
ically relevant approach of chronic systemic delivery, IGF-1 suppressed
the autoimmune response in multiple mouse models of autoimmune
disease (type 1 diabetes and multiple sclerosis). IGF-1 specifically
induced the proliferation of human or mouse Treg cells, with no effect
on other pro-inflammatory T-cell subsets. Importantly, this stimula-
tory effect, either in vivo or in vitro, was dependent on a functional
IGF-1 receptor, demonstrating the cell-type specificity of IGF-1 action
on the adaptive immune system, explaining the observed improve-
ment in autoimmune disease and further supporting the hypothesis
that systemically delivered IGF-1 is able to re-establish tolerance to
self antigens by increasing Treg cell proliferation.
Impact
Our findings provide the rationale and preclinical groundwork for the
use of recombinant IGF-1 in multiple common and devastating auto-
immune diseases such as type 1 diabetes and multiple sclerosis, as
well as other applications including transplantation tolerance in graft-
versus-host disease, fetomaternal tolerance during pregnancy and the
control of excessive immune response to microbes and allergens. By
directly implicating IGF-1 in Treg cell function, we also provide the
basis for understanding its mode of action, which will help in the
search of appropriate clinical and surrogate markers for clinical trial
design. These results will also inform new combinations of IGF-1 with
other drugs (anti-inflammatory or immunosuppressant) as long as
they do not compromise Treg cell expansion and enough time is given
for tolerance to develop. Given that rhIGF-1 is already an approved
drug for the treatment of severe primary IGF-I deficiency and has
already been tested in a variety of clinical settings, human trials for
its use in the treatment of autoimmune and inflammatory disorders
can be implemented without delay. Together with our previous work,
and new findings linking Treg action to tissue repair, this study high-
lights the potential of this growth factor for orchestrating the requi-
site cells and molecules essential to restore tissue functionality and
repress fibrosis, atrophy or perpetuation of non-resolving inflamma-
tion during regeneration.
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performed using FloJo (Tree Star Inc.) or FACS Diva software (BD
Biosciences). When a representative example is shown, the experi-
ment was repeated at least three times.
Suppression experiments were performed with sorted FACS-
purified splenic cells. Briefly, sorted CD4-positive CD25-negative
cells were first stained with carboxyfluorescein diacetate succini-
midylester (CFSE) (Molecular Probes). Cells were then cultured for
3 days in 96-well plates with irradiated antigen-presenting spleno-
cytes (30 Gy), soluble anti-CD3 (145.2C11; eBioscience) and the
indicated ratios of CD4 CD25 double-positive cells previously
treated with rhIGF-1. The percentages of proliferating and non-
proliferating cells were then used to calculate the degree of
suppression.
Gene expression profiling
Treg cells were isolated from spleens of Foxp3cre/gfp mice, purified
by FACS (CD4+ CD25+ GFP+), incubated with rhIGF-1 for 2 days
and further purified by FACS. RNA was prepared with the RNeasy
Mini Kit according to the manufacturer’s instructions (Qiagen). Two
rounds of RNA amplification, labelling and hybridization to M430
2.0 chips (Affymetrix) were done at the EMBL Gene Core Facility in
Heidelberg. Microarray data were analyzed using the GeneSpring
software, and differential expression was defined by two-fold with a
false discovery rate of P < 0.05. Microarray results were confirmed
by quantitative RNA analysis performed by real-time PCR using
Taqman probes (Applied Biosystems, Life Technologies) corre-
sponding to a subset of genes (stat1, bcl1 1b, map3k2, mapk1,
tnfsf11, cd44, crebp and foxo1). The mRNA amounts were normal-
ized to those of the hprt gene. Transcription target enrichment
analyses were performed using the web-based tool WebGestalt2
(Zhang et al, 2005; Duncan et al, 2010). The microarray data
performed in this study were submitted to ArrayExpress database
[http://www.ebi.ac.uk/arrayexpress/] and received the accession
number E-MTAB-2951.
Statistics
All analyses were performed with Prism 5.0 (GraphPad Software
Inc.). Unless otherwise indicated, statistical analyses were
performed by a nonparametric Mann–Whitney U-test or Student’s
t-test and graphs show the mean and standard error. Specific tests
and significance levels are found in figure legends.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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